Full Press Release Details
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Presents Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in PBH at ObesityWeek® 2026 Annual Meeting
AMLX Positive Sentiment
Amylyx Pharmaceuticals Presents Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting
Key Takeaway: Amylyx Pharmaceuticals announced the results of its Phase 3 LUCIDITY clinical trial for Avexitide, targeting post-bariatric hypoglycemia. The findings were presented at the ObesityWeek® 2026 Annual Meeting, highlighting the company's ongoing research in this area.
Market Sentiment Analysis
POSITIVE FACTORS
- Amylyx Pharmaceuticals presented results from a Phase 3 trial.
- The trial focused on Avexitide for post-bariatric hypoglycemia.
- Results were shared at the prestigious ObesityWeek® 2026 Annual Meeting.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+211%
120-day peak, hindsight
Typical move
29.2%
average across 3 past catalysts
Cash runway
~68 mo
Low dilution risk
Lead asset
AMX0035
Phase 3 · Progressive Supranuclear Palsy
Frequently Asked Questions
What is the LUCIDITY trial?
It is a Phase 3 clinical trial evaluating Avexitide for treating post-bariatric hypoglycemia.
Where were results presented?
Amylyx presented these findings at the ObesityWeek 2026 Annual Meeting in Cambridge, Mass.
What condition does Avexitide target?
Avexitide targets post-bariatric hypoglycemia, a condition affecting patients after bariatric surgery.
Who conducted the trial?
Amylyx Pharmaceuticals conducted and presented the Phase 3 LUCIDITY trial results.